Antiretroviral therapy for pregnant women

American Journal of Obstetrics and Gynecology

Volumn 176, Issue 2, 1997, Pages 478-489

  Minkoff, H ^a   Augenbraun, M ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

antiretroviral therapy; Human immunodeficiency virus; mother to child transmission

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PLACENTAL TRANSFER; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

EID: 0031019154     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(97)70519-2     Document Type: Article

References (83)

1. Centers for Disease Control and Prevention CDC recommendations of the U.S. Public Health Service task force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus MMWR Morb Mortal Wkly Rep 43 1994 1 20
2. EM Connor RS Sperling R Gelber P Kiselev G Scott MJ O'Sullivan Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment N Engl J Med 331 1994 1173 1180
3. HL Minkoff J. Moreno Drug prophylaxis for human immunodeficiency virus infected pregnant women: ethical considerations Am J Obstet Gynecol 163 1990 1111 1114
4. P Statton LM Mofenson AD. Willoughby Human immunodeficiency virus in pregnant women under care at AIDS clinical trials centers in the United States Obstet Gynecol 779 1992 364 368
5. M Fischl D Richman M Grieco M Gottlieb P Volberding O Laskin The efficacy of ZDV in the treatment of patients with AIDS and AIDS-related complex: a double blind placebo controlled trial N Engl J Med 317 1987 185 191
6. M Fischl C Parker C Pettinelli M Wulfsohn M Hirsch A Collier A randomized controlled trial of reduced daily dose of ZDV in patients with acquired immunodeficiency syndrome: the AIDS Clinical Trials Group N Engl J Med 323 1990 1009 1014
7. M Fischl D Richman N Hansen A Collier J Carey M Para The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection, a double blind placebo controlled trial: the AIDS Clinical Trials Group Ann Intern Med 112 1990 727 737
8. M Sande C Carpenter G Cobbs K Holmes J. Sanford Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference JAMA 270 1993 2582 2589
9. J Hamilton P Hartigan M Simberkoff P Day G Diamond G Dickinson A controlled trial of early versus late treatment with ZDV in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs Cooperative Study N Engl J Med 326 1992 437 443
10. Concorde Coordinating Committee Concorde: MRC/ANRS randomized double blind controlled trial of immediate and deferred ZDV in symptom free HIV infection Lancet 343 1994 871 878
11. SE Lipschutz EJ Orav SP Sanders AR Hale K McIntosh SD. Colan Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine N Engl J Med 327 1992 1260 1265
12. KM. Ayers Preclinical toxicology of zidovudine: an overview Am J Med 85 Suppl 2A 1988 186 188
13. Physicians' desk reference 48th ed 1994 : Medical Economics Montvale (NJ)
14. P Toltzis CM Marx N Kleinman EM Levine EV. Schmidt Zidovudine-associated embryonic toxicity in mice J Infect Dis 163 1991 1212 1218
15. P Toltzis T Mourton T. Magnuson Effect of zidovudine on preimplantation murine embryos Antimicrob Agents Chemother 37 1993 1610 1613
16. Comprehensive information for investigators: retrovir 1993 : Burroughs Wellcome Research Triangle Park (NC)
17. RS Sperling PO Stratton MJ Sullivan B Boyer DH Watts JS Lambert A survey of zidovudine use in pregnant women with human immunodeficiency virus infection N Engl J Med 326 1992 857 861
18. MJ O'Sullivan PJJ Boyer GB Scott WP Parks S Weller MR Blum The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082) Am J Obstet Gynecol 168 1993 1510 1516
19. DH Watts ZA Brown T Tartaglione SK Burchett K Opheam R Coombs Pharmacokinetic disposition of during pregnancy J Infect Dis 163 1991 226 232
20. A Ferrazin A de Mafia C Gotta V Mazzarello A Canessa B Ciravegna Zidovudine therapy of HIV-1 infection during pregnancy: assessment of the effect on the newborns J Acquir Immune Defic Syndr 6 1993 376 379
21. PJJ Boyer M Dillon M Navaie A Deveikis M Keller S O'Rourke Factors predictive of maternal-fetal transmission of HIV-l: preliminary analysis of zidovudine (ZDV) given during pregnancy and/or delivery JAMA 271 1994 1925 1930
22. E Connor R Sperling D Shapiro J Oleske MG. Fowler Long term effect of ZDV exposure among uninfected infants born to HIV-infected mothers in AIDS clinical trials group 076 Proceedings of the thirty-fifth annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sept 17-20, San Francisco 1995 The Conference San Francisco: 205
23. Centers for Disease Control and Prevention Birth outcomes following zidovudine therapy in pregnant women MMWR Morb Mortal Wkly Rep 43 1994 409 416
24. DD Richman JM Grimes SW. Lagakos Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus J Acquir Immune Defic Syndr 3 1990 743 746
25. MS Hirsch RT. Aquila Therapy for human immunodeficiency virus infection N Engl J Med 328 1993 1686 1695
26. MS Smith KL Koerber JS. Pagano Long-term persistence of zidovudine resistance mutations in plasma isolates from human immunodeficiency virus type 1 of didexoyinosine-treated patients removed from zidovudine therapy J Infect Dis 169 1994 184 188
27. A Schindzielorz I Pike M Daniels L Pacelli L. Smaldone Rates and risk factors for adverse events associated with didanosine in the expanded access program Clin Infect Dis 19 1994 1076 1083
28. R Dolin D Amato M Fischl C Pettinelli M Beltangady S Liou ZDV compared with didahosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine Arch Int Med 155 1995 961 974
29. S Spruance A Pavia D Peterson A Berry R Pollard T Patterson Didanosine compared with continuation of zidovudine in HIV infected patients with signs of clinical deterioration while receiving zidovudine, a randomized double blind clinical trial: the Bristol-Myers Squibb A1454-010 Study Group Ann Intern Med 120 1994 360 368
30. J Kahn S Lagakos D Richman A Cross C Pettinelli S. Liou A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency syndrome infection: the NIAID AIDS Clinical Trials Group N Engl J Med 327 1992 581 587
31. JC Pons MC Boubon AM Taburet E Singlas V Chambrin R Frydman Fetoplacental passage of 2`,3`-dideoxyinosine Lancet 337 1991 732
32. RE Bawdon S Sobhi J. Dax The transfer of antihuman immunodeficiency virus nucleoside compounds by the term human placenta Am J Obstet Gynecol 167 1992 1570 1574
33. T Meng M Fischl A Boote S Spector D Bennet Y. Bassiabos Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study Ann Intern Med 116 1992 13 20
34. W Silkker Jr GD Lipe SF Ali L Schmued AC Scatlet Z. Binienda Placental transfer and fetal distribution of 3H-ddC in the monkey Teratology 45 1992 457 458
35. P Lindstrom M Harris AM Hoberman JK Dunnick RE. Morrissey Developmental toxicity of 2`3`-dideoxycytidine (DDC) in mice Teratology 42 1990 131 136
36. M Foerster U Kastner R. Neubert Effect of six virustatic nucleoside analogues on the development of fetal rat thymus in organ culture Arch Toxicol 66 1992 688 699
37. S. Nightingale From the Food and Drug Administration JAMA 272 1994 582
38. P Lin H Samanta R Rose A Patrick J Trimble C. Bechtold Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates for patients on prolonged stavudine therapy J Infect Dis 170 1994 1157 1160
39. P Toltzis T Mourton T. Magnuson Comparative embryonic cytotoxicity of antiretroviral nucleosides J Infect Dis 169 1994 1100 1102
40. D Merril M Moonis T Chou M. Hirsch Lamivudine or stavudine in 2- and 3 drug combinations against human immunodeficiency type 1 replication in vitro J Infect Dis 173 1996 355 364
41. J Dienstag R Perrillo E Schiff M Barhtolomew C Vicary M. Rubin A preliminary trial of lamivudine for chronic hepatitis B infection N Engl J Med 333 1995 1657 1661
42. J Eron S Benoit J Jemsek RD MacArthur J Santana JB Quinn Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200-500 CD4 cells per cubic millimeter N Engl J Med 333 1995 1662 1669
43. 3: a phase II study [abstract] Proceedings of the third conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1; Washington (DC) 1996 : The Conference Washington (DC)
44. R Schuurman M Nijhuis R van Leeuwen P Schipper D de Jong P Collis Rapid changes in human immunodeficiency virus type 1 RNA local and appearance of drug-resistant virus populations in persons treated with lamivudine (3 TC) J Infect Dis 171 1995 1411 1419
45. B Larder S Kemp P. Harrigan Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination treatment Science 269 1995 696 699
46. MA Johnson C Goodwin GJ Yuen MD Gray R Plumb H Cavadia The pharmacokinetics of 3TC administered to HIV-1 infected women (prepartum, during labor, and postpartum) and their offspring Proceedings of the Eleventh International Conference on AIDS, 1996 July 7-12; Vancouver (BC) 1996 The Conference Vancouver 445
47. C. Ezzel Emergence of the protease inhibitors: a better class of AIDS drugs? J NIH Res 8 1996 41 45
48. TJ McQuade AG Tomasseli L Liu V Karacostas B Moss TK Sawyer A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-1 like particle maturation Science 247 1990 454 456
49. A Collier R Coombs D Schoenfeld R Basset J Timponi A Baruch Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitibine N Engl J Med 334 1996 1011 1017
50. SA Danner A Carr J Leonard LM Lehman F Gudiol A Raventos A short term study of the safety pharmacokinetics and efficiency of ritonavir an inhibitor of HIV-1 protease N Engl J Med 333 1995 1528 1533
51. M Markowitz M Saag W Powderely AM Hurley A Hsu JM. Valdes A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection N Engl J Med 333 1995 1543 1549
52. D Mathez P De Truchis I Gorin C Katlama G Pialoux A Saimot Ritonavir, AZT, ddC as a triple combination in AIDS patients [abstract] Proceedings of the third conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1; Washington (DC) 1996 : The Conference Washington (DC)
53. B Cameron M Heath-Chiozzi S Kravcik R Mills A Potthoff D Henry Prolongation of life and prevention of AIDS in advanced immunodeficiency with ritonavir [abstract] Proceedings of the third conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1; Washington (DC) 1996 : The Conference Washington (DC)
54. American College of Obstetricians Gynecologists Human immunodeficiency virus infection 1992 : The College Washington (DC) Technical Bulletin No.: 162
55. F Massari M Conant J Mellors R Steigbigil D Mildvan R Greenberg A phase II open label, randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (ddI) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients [abstract] Proceedings of the third conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1; Washington (DC) 1996 : The Conference Washington (DC)
56. R Gulick J Mellors D Havlir J Eron C Gonzalez E McMahon Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) [abstract] Proceedings of the third conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1; Washington (DC) 1996 : The Conference Washington (DC)
57. R D'Aquila M Hughes V Johnson MA Fischl JP Sommadossi S Liou Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection Ann Intern Med 124 1996 1019 1030
58. J Hamilton P Hartigan M Simberkoff P Day G Diamond G Dickinson A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs Cooperative Study N Engl J Med 326 1992 437 443
59. Concorde Coordinating Committee Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom free HIV infection Lancet 343 1994 871 881
60. J. Stephenson New anti-HIV drugs and treatment strategies buoy AIDS researchers JAMA 275 1996 579 580
61. J. Stephenson Other AIDS drug regimens beat AZT alone reduce clinical progression and mortality JAMA 274 1995 1183 1184
62. W. Choo Combination superior to zidovudine in the Delta trial Lancet 346 1995 895
63. J Mellors L Kingsley C Rinaldo J Todd B Hoo R Kokka Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion Ann Intern Med 122 1995 573 579
64. D Ho A Neumann A Perelson W Chen J Leonard M. Markowitz Rapid turnover of plasma virions and CD4 lymphocyte in HIV-1 infection Nature 373 1995 123 126
65. R Pollard D Peterson D Hardy L Pedneautt C McLaren J Skouronski Antiviral effect and safety of stavudine (D4T) and didanosine(ddI) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blinded trial [abstract] Proceedings of the third conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1; Washington (DC) 1996 : The Conference Washington (DC)
66. W-144' 962. Ro 31-8959 saquinavir: investigational drug brochure 1995 April Hoffmann-La Roche third version
67. H Jacobsen M Hanggi M Ott I Duncan S Owen M Andreon In vivo resistance to an HIV-1 protease inhibitor: mutations, kinetics and frequencies J Infect Dis 173 1996 1379 1387
68. P Volberding S Lagakos J Grimes DS Stein J Rooney TC Meng A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter N Engl J Med 333 1995 401 407
69. S Kinloch-De Loes B Hirschel B Hoen DA Cooper B Tindall A Carr A controlled trial of zidovudine in primary human immunodeficiency virus infection N Engl J Med 333 1995 408 413
70. J Mellors C Rinaldo P Gupta R White J Todd L. Kingley Prognosis in HIV-1 infection predicted by the quantity of virus in plasma Science 272 1996 1167 1170
71. M Saag M Holodny D Kuritzkes W O'Brien R Coombs M Poschor HIV viral load markers in clinical practice Nat Med 2 1996 625 630
72. C Carpenter M Fischl S Hammer MS Hirsh DM Jacobsen DA Katzenstein Consensus Statement: antiretroviral therapy for HIV infection in 1996 JAMA 276 1996 146 154
73. RS Sperling P Stratton J O'Sullivan B Boyer DH Watts JS Lambert A survey of zidovudine use in pregnant women with immunodeficiency virus infection N Engl J Med 326 1992 857 861
74. MJ O'Sullivan PJJ Boyer GB Scott WP Parks S Weller MR Blum The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I Acquired Immunodeficiency Syndrome Clinical Trials Group study (protocol 082) Am J Obstet Gynecol 168 1993 1510 1516
75. G Fang H Burger R Grimson B Tropper S Nachman D Mayers Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission Proc Natl Acad Sci U S A 92 1995 12100 12104
76. RE Dickover EM Garratty SA Herman S Myung-Shin S Plaeger PJ Boyer Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission JAMA 275 1996 599 605
77. S Landesman D. Burns Quantifying HIV JAMA 275 1996 640 641
78. SM Wolinsky CM Wike BT Korber C Hutto WP Parks LL Rosenblum Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants Science 255 1992 1134 1137
79. In re AC. 573 A2d1235 (CD Ct App), 1990.
80. FA Chervenak LB. McCullough What is obstetric? Ethics Clin Obstet Gynecol 35 1992 709 719
81. PS. Rosenberg Scope of the AIDS epidemic in the United States Science 270 1995 1372 1375
82. A Sunderland HL Minkoff J Handte G Moroso S. Landesman The influence of serostatus on women's reproductive decisions Obstet Gynecol 79 1992 102731
83. PA Selwyn RJ Carter EE Schoenbaum VJ Robertson RS Klein MF. Rogers Knowledge of HIV antibody status and decisions to continue or terminate pregnancy among intravenous drug users JAMA 261 1989 3567 3571